col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


56 Results       Page 1

 [1] 
Informa UK (Taylor & Francis): Leukemia & Lymphoma
  original article Date Title Authors   All Authors
1 [GO] 2024―Apr―16 COVID-19 antibody titers after tixagevimab-cilgavimab injection in patients with hematologic diseases; a single-center, prospective study Naokazu Nakamura, Hiroko Tsunemine, Ryo Ikunari, Tomomi Sakai, Nobuyoshi Arima
2 [GO] 2023―Nov―15 The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey Shaimaa El-Ashwah, Jon Salmanton-García, Yavuz M. Bilgin, Federico Itri, Pavel Žák, Barbora Weinbergerová, et al. (+55)
3 [GO] 2023―Oct―20 Cutaneous lymphoproliferative disorders after COVID-19 vaccination: clinical presentation, histopathology, and outcomes Emily R. Gordon, Bradley D. Kwinta, Celine M. Schreidah, Lauren M. Fahmy, Oluwaseyi Adeuyan, Dawn Queen, et al. (+3)
4 [GO] 2023―Sep―21 Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL Emily Tomasulo, Shira Paul, Rui Mu, Xin Tian, Jonathan Chen, Christopher Pleyer, et al. (+2)
5 [GO] 2023―Aug―21 Improved COVID-19 outcomes in CAR-T patients in the age of vaccination and preemptive pharmacotherapeutics Kathleen P. L. Cheok, Amy A. Kirkwood, Thomas Creasey, Eleni Tholouli, Sridhar Chaganti, Amrith Mathew, et al. (+12)
6 [GO] 2023―Aug―14 Lessons learned from COVID-19 pandemic: outcomes after SARS-CoV-2 infection in hematopoietic cell transplant and cell therapy recipients Joe S. Al-Ramahi, Moazzam Shahzad, Kevin Li, Shaun DeJarnette, Sibgha Gull Chaudhary, Forat Lutfi, et al. (+9)
7 [GO] 2023―Jun―21 Breakthrough COVID-19 is mild in vaccinated patients with hematological malignancy receiving tixagevimab-cilgavimab as pre-exposure prophylaxis V. G. Hall, C. Lim, N. R. Saunders, E. Klimevski, T. H. O. Nguyen, L. Kedzierski, et al. (+7)
8 [GO] 2023―Mar―16 Virtual care for multiple myeloma in the COVID-19 era: interrupted time series analysis of veterans health administration data Christopher T. Su, Jason C. Chen, Jeremy B. Sussman
9 [GO] 2023―Mar―13 Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir Tamar Tadmor, Guy Melamed, Tal Patalon, Hilel Alapi, Lior Rokach
10 [GO] 2023―Mar―13 Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemia Matteo Passerini, Tamar Ratishvili, Jonathon M. Monroe, Zelalem Temesgen, Thomas E. Witzig, Neil E. Kay, et al. (+2)
11 [GO] 2022―Nov―01 SARS-CoV-2 infection in patients with primary central nervous system lymphoma in the vaccination era Alice Laurenge, Renata Ursu, Emeline Tabouret, Vincent Harlay, Guido Ahle, Sylvain Choquet, et al. (+10)
12 [GO] 2022―Oct―25 Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndrome David C. Helfgott, Sabrina Racine-Brzostek, Kelsey J. Short, Zhen Zhao, Paul Christos, Itzel Nino, et al. (+6)
13 [GO] 2022―Aug―22 Successful provision of CAR-T therapy during a pandemic: low SARS-CoV-2 infection rates and reduction in ICU admissions following modification of patient pathway Luke Carter-Brzezinski, Elizabeth Davies, Jane Norman, Lourdes Rubio, Christopher Dixon, Sarah Brett, et al. (+8)
14 [GO] 2022―Jun―21 Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic Aditya Tedjaseputra, James A. Kuzich, Nisha Thiagarajah, Tse-Chieh Teh, Julia McClelland, Marzia Rahman, et al. (+10)
15 [GO] 2022―Jun―19 Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak Milena Kohn, Tamim Alsuliman, Sylvain Lamure, Morgane Cheminant, Jéremy Delage, Corinne Merle De Boever, et al. (+13)
16 [GO] 2022―May―20 High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination Lauren C. Shapiro, Astha Thakkar, Radhika Gali, Jesus D. Gonzalez-Lugo, Abdul-Hamid Bazarbachi, Shafia Rahman, et al. (+14)
17 [GO] 2022―May―14 Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination Lara Howells, Wei Yee Chan, Emilie Sanchez, Jacqueline Horder, Fiona Newrick, Jotham Marfil, et al. (+13)
18 [GO] 2022―Apr―28 Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis Kathleen P. L. Cheok, Amy A. Kirkwood, Tobias Menne, Eleni Tholouli, Sridhar Chaganti, Amrith Mathew, et al. (+12)
19 [GO] 2022―Mar―27 How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia Marina Deodato, Anna Maria Frustaci, Paolo Sportoletti, Luca Laurenti, Roberta Murru, Andrea Visentin, et al. (+19)
20 [GO] 2022―Feb―27 COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience Neha Mehta-Shah, Nancy L. Bartlett, Brad Kahl, Marcus P. Watkins, Amalia Dubois, Gabby Schmelzle, et al. (+4)
21 [GO] 2022―Feb―14 COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study Оlga L. Kochneva, Maria Kislova, Evgenya I. Zhelnova, Andrei A. Petrenko, Elena A. Baryakh, Konstantin V. Yatskov, et al. (+8)
22 [GO] 2022―Feb―02 Anti CD20-based immunochemotherapy abolishes antibody response to Covid-19 mRNA vaccine in lymphoma patients vaccinated during active first line treatment Silvia Bellesi, Michela Sali, Elena Maiolo, Maria del Carmen Pereyra Boza, Eleonora Alma, Ivana Palucci, et al. (+7)
23 [GO] 2022―Jan―24 Long-term persistence of natural anti-SARS-CoV-2 antibodies and mild impact of SARS-CoV-2 infection in CML patients: results from a seroprevalence study Simone Claudiani, Eleanor L. Parker, Dragana Milojkovic, Carolina Rosadas, Afzal Khan, Ksenia Katsanovskaja, et al. (+6)
24 [GO] 2022―Jan―06 Telehealth access among hematology patients during the COVID-19 pandemic in Australia: a cross-sectional survey Nienke Zomerdijk, Michelle I Jongenelis, Jane Turner, Kathryn Huntley, Andrew Smith, Camille E. Short
25 [GO] 2021―Oct―28 Cellular response to COVID-19 vaccines in hematologic malignancies patients: a new hope for non-responders? Imane Saad Albichr, Julien De Greef, Eric Van Den Neste, Xavier Poiré, Violaine Havelange, Marie-Christiane Vekemans, et al. (+5)
26 [GO] 2021―Oct―21 Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients José Luis Piñana, Lourdes Vázquez, Rodrigo Martino, Rafael de la Cámara, Anna Sureda, Rebeca Rodríguez-Veiga, et al. (+25)
27 [GO] 2021―Oct―20 COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies Franziska Modemann, Christian Niederwieser, Katja Weisel, Carsten Bokemeyer, Walter Fiedler, Susanne Ghandili
28 [GO] 2021―Sep―15 Worsening of COVID-19 after chemotherapy in patients considered to have recovered from a SARS-CoV-2 infection Arthur Poncelet, Gil Verschelden, Martin Colard, Marc Hildebrand, Maya Hites, Nicolas Yin, et al. (+3)
29 [GO] 2021―Sep―02 Improvement in mortality of hospitalized patients with hematological malignancies in the 2nd wave of COVID-19 in the UK: experience of a large London NHS trust Richard Hinton, George Nesr, Catherine Garnett, David Foldes, Joel James Robert McCay, Rachael Medland, et al. (+6)
30 [GO] 2021―Aug―26 Excess of deaths for patients with plasma cell proliferative disorders as a result of the COVID-19 pandemic Tom Dunne, Douglas Stewart, Holly Lee, Jason Tay, Peter Duggan, Sylvia McCulloch, et al. (+3)
31 [GO] 2021―Aug―18 COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome Ilana Levy, Avital Lavi, Eran Zimran, Sigal Grisariu, Shlomzion Aumann, Gilad Itchaki, et al. (+26)
32 [GO] 2021―Aug―13 Acute leukemia and SARS-CoV-2 infection: clinical characteristics and risk factors for mortality Mirjana Mitrovic, Nikola Pantic, Nikica Sabljic, Miodrag Vucic, Zoran Bukumiric, Marijana Virijevic, et al. (+5)
33 [GO] 2021―Jul―27 Between a rock and a hard place: COVID-19 vaccination and patients on rituximab therapy Benjamin W. Teh, Constantine S. Tam
34 [GO] 2021―Jul―22 Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group Tomás Palanques-Pastor, Juan Eduardo Megías-Vericat, Pilar Martínez, José Luis López Lorenzo, Javier Cornago Navascués, Gabriela Rodriguez Macias, et al. (+37)
35 [GO] 2021―Jul―15 Systematic screening for SARS-CoV-2 in patients with hematological malignancies on active anticancer treatment in the outpatient setting Marzia Varettoni, Silvia Mangiacavalli, Sara Rattotti, Claudio Salvatore Cartia, Chiara Cavalloni, Franca Rossetti, et al. (+13)
36 [GO] 2021―Jul―13 COVID-19 in chronic myeloid leukemia patients in Latin America Katia B. Pagnano, Evelyn Herrera Peralta, Juan Ramon Navarro, Lourdes del Rosario David Salas, Nancy Delgado, Beatriz Moiraghi, et al. (+23)
37 [GO] 2021―Jun―28 Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality Maximilian Stahl, Varun Narendra, Justin Jee, Andriy Derkach, Molly Maloy, Mark B. Geyer, et al. (+6)
38 [GO] 2021―Jun―24 Impact of COVID-19 on peripheral blood stem cell mobilization for myeloma patients Marquita Camilleri, Thomas McGrath, William Wilson, Stuart J. Ings, Jacqueline Horder, Fiona Newrick, et al. (+6)
39 [GO] 2021―Jun―21 COVID-19 vaccination in patients on rituximab: a survey of lymphoma physicians at NCI designated cancer centers Marcus Messmer, Nina Wagner-Johnston
40 [GO] 2021―May―11 Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination Caitlin M. Brumfiel, Meera H. Patel, David J. DiCaudo, Allison C. Rosenthal, Mark R. Pittelkow, Aaron R. Mangold
41 [GO] 2021―Mar―17 Convalescent hyperimmune plasma in patients with hematologic malignancies and severe COVID-19 infections Alain Mina, Sara Small, Leonidas C. Platanias
42 [GO] 2021―Feb―28 Lessons learned for successful treatment of AML in the second wave of COVID-19 outbreak A. Ramírez-López, P. Lázaro del Campo, K. Humala, B. De la Cruz Benito, I. Sánchez-Vadillo, A. López de la Guía, et al. (+3)
43 [GO] 2021―Feb―23 Severe IgA-mediated autoimmune hemolytic anemia triggered by SARS-CoV-2 infection Aude Mausoleo, Soledad Henriquez, Cécile Goujard, Anne-Marie Roque-Afonso, Nicolas Noel, Olivier Lambotte
44 [GO] 2021―Jan―29 Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort Talvinder Bhogal, Umair T. Khan, Rebecca Lee, Alexander Stockdale, Christian Hesford, Vaishnav Potti-Dhananjaya, et al. (+17)
45 [GO] 2021―Jan―22 Anemia and red blood cell abnormalities in COVID-19 Philip Murphy, Siobhan Glavey, John Quinn
46 [GO] 2021―Jan―19 Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies Silvia Ferrari, Chiara Caprioli, Alessandra Weber, Alessandro Rambaldi, Federico Lussana
47 [GO] 2021―Jan―10 Severe COVID-19 infection in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab therapy Alexis Genthon, Thibault Chiarabini, Pierre Baylac, Nadia Valin, Tomas Urbina, Jérome Pacanowski, et al. (+7)
48 [GO] 2020―Dec―26 Evolving management strategies for lymphomas during the COVID-19 pandemic Noemie Lang, John Kuruvilla
49 [GO] 2020―Dec―03 COVID-19 in patients with multiple myeloma: a cross-sectional survey from the most severely affected region in China Chunyan Sun, Junying Li, Hang Xiang, Chunrui Li, Anfang Shang, Wei Chang, et al. (+13)
50 [GO] 2020―Nov―10 Outcome of hospitalized patients with hematological malignancies and COVID-19 infection in a large urban healthcare trust in the United Kingdom Catherine Garnett, David Foldes, Chris Bailey, George Nesr, Tracy Hui, Richard Hinton, et al. (+10)
51 [GO] 2020―Sep―09 Efficacy and safety of ruxolitinib for Covid-19 related acute respiratory distress syndrome in a patient with blastic plasmacytoid dendritic cell neoplasm (leukemic variant) Vincenzo Sammartano, Adele Santoni, Bruno Frediani, Anna Sicuranza, Cencini Emanuele, Federico Franchi, et al. (+2)
52 [GO] 2020―Aug―25 Clinical characteristics, therapeutic management, and prognostic factors of adult COVID-19 inpatients with hematological malignancies Yaogong Wu, Wenlan Chen, Wenjing Li, Miaomiao Zhao, Qiuzhe Wei, Xiaoping Zhang, et al. (+3)
53 [GO] 2020―Jul―23 The management of chronic lymphoproliferative disorders at the time of SARS-Covid2 pandemic: weathering the storm Anna Maria Frustaci, Giulia Zamprogna, Marina Deodato, Roberto Cairoli, Marco Montillo, Alessandra Tedeschi
54 [GO] 2020―Jul―09 Hematological manifestations of COVID-19 Alain Mina, Koen van Besien, Leonidas C. Platanias
55 [GO] 2020―Jul―02 Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection Claudio Galvao de Castro Jr., Lauro Jose Gregianin, Jan A. Burger
56 [GO] 2020―Jun―17 SARS-CoV-2 in multiple myeloma: initial observation and management Elisabet E. Manasanch, Victor Mulanovich, Joanna-Grace Manzano, Maria Susan Gaeta, Melody Becnel, Gregory P. Kaufman, et al. (+9)
 [1] 

56 Results       Page 1



[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.004 sec